Discontinued — last reported Q4 '25
Otezla (apremilast) — Total revenues
Products & Services · Total revenuesAmgen Otezla (apremilast) — Total revenues remained flat by 0.0% to $566.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.5%, from $531.50M to $566.25M. Over 2 years (FY 2023 to FY 2025), Otezla (apremilast) — Total revenues shows relatively stable performance with a 1.7% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market adoption or successful commercial execution, while a decrease may signal increased competition or patent expiration.
Detailed definition
This represents the total gross sales generated by a specific pharmaceutical product line within the company's portfolio...
Peer comparison
Comparable to product-level revenue reporting in other major biopharmaceutical companies.
amgn_segment_otezla_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $534.00M | $609.00M | $451.00M | $594.00M | $547.00M | $547.00M | $547.00M | $547.00M | $531.50M | $531.50M | $531.50M | $531.50M | $566.25M | $566.25M | $566.25M | $566.25M |
| QoQ Change | — | +14.0% | -25.9% | +31.7% | -7.9% | +0.0% | +0.0% | +0.0% | -2.8% | +0.0% | +0.0% | +0.0% | +6.5% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | +11.2% | +21.3% | -7.9% | — | — | -2.8% | -2.8% | -2.8% | -2.8% | +6.5% | +6.5% | +6.5% | +6.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Amgen's otezla (apremilast) — total revenues?
- Amgen (AMGN) reported otezla (apremilast) — total revenues of $566.25M in Q4 2025.
- How has Amgen's otezla (apremilast) — total revenues changed year-over-year?
- Amgen's otezla (apremilast) — total revenues increased by 6.5% year-over-year, from $531.50M to $566.25M.
- What is the long-term trend for Amgen's otezla (apremilast) — total revenues?
- Over 2 years (2023 to 2025), Amgen's otezla (apremilast) — total revenues has grown at a 1.7% compound annual growth rate (CAGR), from $2.19B to $2.27B.
- What does otezla (apremilast) — total revenues mean?
- The total amount of money earned from sales of a specific drug product.